Evidence map›Paper›PMID 38638446›Full record

ReviewTobacco prevention & cessation2024

Tobacco endgame measures and their adaptation in selected European countries: A narrative review synthesis.

Otto Ruokolainen, Hanna Ollila, Tiina Laatikainen, Salla-Maaria Pätsi, Giulia Carreras, Giuseppe Gorini, Dolors Carnicer-Pont, Zsuzsa Cselkó, Romain Guignard, Maria Karekla and 7 more

Abstract readReview
In one paragraph

Review in Tobacco prevention & cessation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Plain Packaging: One of the Plain Simple Solutions for Nicotine Reduction in the Middle East.International journal of environmental research and public health · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Otto RuokolainenDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Hanna OllilaDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Tiina LaatikainenDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Salla-Maaria PätsiDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Giulia CarrerasInstitute for Cancer Research, Prevention and Clinical Network, Florence, Italy.
Giuseppe GoriniInstitute for Cancer Research, Prevention and Clinical Network, Florence, Italy.
Dolors Carnicer-PontGrupo de Investigación en Control del Tabaco, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Zsuzsa CselkóNational Korányi Institute of Pulmonology, Budapest, Hungary.
Romain GuignardPrevention and Health Promotion Department, Santé publique France, Saint-Maurice, France.
Maria KareklaUniversity of Cyprus, Nicosia, Cyprus.
Biljana KilibardaInstitute of Public Health of Serbia 'Dr Milan Jovanovic Batut', Belgrade, Serbia.
Helena KoprivnikarNational Institute of Public Health, Ljubljana, Slovenia.
Angeliki LambrouDirectorate of Epidemiology and Prevention of Non-Communicable Diseases and Injuries, National Public Health Organization, Athens, Greece.
Viêt Nguyen-ThanhPrevention and Health Promotion Department, Santé publique France, Saint-Maurice, France.
Efstathios PapachristouDirectorate of Epidemiology and Prevention of Non-Communicable Diseases and Injuries, National Public Health Organization, Athens, Greece.
Sotiria SchoretsanitiDirectorate of Epidemiology and Prevention of Non-Communicable Diseases and Injuries, National Public Health Organization, Athens, Greece.
Milena VasicInstitute of Public Health of Serbia 'Dr Milan Jovanovic Batut', Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the continued detrimental effects of tobacco use, a growing number of countries are embracing the idea of tobacco endgame, meaning ending the tobacco epidemic instead of controlling it. This narrative review aims to synthesize and update the evidence from earlier scientific reviews on effective tobacco endgame measures, as well as to assess their integration to current national strategies among European countries with official tobacco endgame goals. The synthesis of the prior scientific literature found most evidence on product-focused and some evidence for supply-focused policies. Little evidence was detected for user- and institutional-focused measures. An update for the tobacco-free generation measure showed uncertainty in reducing smoking prevalence, especially for adolescents' reactions to age-restrictive laws. All the countries that established a tobacco endgame strategy have included product standards in their measures, predominantly based on European Union regulations on conventional tobacco products, yet standards above this level and considering other products were also common. Cessation measures were given strong emphasis in strategies, yet none of the countries linked these to specific endgame measures. Despite commonly mentioning vulnerable groups, such as youth and pregnant women, adoption of measures to reduce tobacco use among these groups was scarce. Lastly, the decline in tobacco use seems to be modest, implying challenges in meeting the endgame goals. To meet these goals, European countries should reinforce the implementation of known effective tobacco control measures such as tax increases. Furthermore, new innovative strategies and measures to meet the objective of an endgame should be explored.

Indexed as

Endgamepolicyreviewsmokingtobaccotobacco control

Identifiers

PMID38638446
PMCPMC11025294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.